What changed in RenovoRx, Inc.'s 2025 10-K compared to 2024?

Across the narrative sections we track, RenovoRx, Inc. (RNXT) added 0 paragraphs, removed 0, and edited 0 between the 2024 and 2025 10-K filings. The biggest movers are .

Where does this RNXT 10-K diff come from?

The source filings are RenovoRx, Inc.'s official 2024 and 2025 Form 10-K annual reports from SEC EDGAR. 10q10k.net parses each filing, aligns paragraphs by section (Item 1, 1A, 1C, 2, 3, 7, 7A), and highlights every added, removed and edited sentence side-by-side.

RenovoRx, Inc.RNXT财报

Nasdaq · 医疗保健 · 药物制剂

深度分析

RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapy delivery systems for cancer treatment. Its core assets include proprietary transarterial delivery platforms, with primary operations in the United States, serving unmet medical needs in the oncology care segment.

What changed in RenovoRx, Inc.'s 10-K — 2024 vs 2025

No meaningful paragraph-level changes detected in the compared sections. Either the two filings are nearly identical or the sections did not parse.